Orexigen Therapeutics Sees Shares Slide Pre-Market; Eli Lily Edges Up

Shares of Orexigen Therapeutics (NASDAQ:OREX) slipped in Tuesday’s pre-market session, after the developer of drug treatments for obesity and related disorders said it received a Day 120 List of Questions regarding the marketing authorization application for its NB32 weight-loss drug candidate from the European Medicines Agency’s Committee for Medicinal Products for Human Use. The company…

Read More

VCA Antech Reports In-Line Results

After the markets closed on Thursday, February 13, VCA Antech (NASDAQ:WOOF) reported fourth-quarter results that were generally in line with expectations. Sales of $435.5 million grew 4.1% from the prior-year period and were a bit shy of the $444.5 million consensus forecast; adjusted earnings per share registered at $0.31—up 10.7% year-over-year and spot on the…

Read More
Gilead Sciences GILD NASDAQ:GILD

Broadsoft Expected to Report Strong Quarter; Sprint Bringing Credibility in Mobile

For fourth quarter 2013, BroadSoft should meet or beat consensus estimates. We expect a large chunk of deferred revenue to come off the balance sheet and billings to show significant improvement sequentially in virtually all areas license, subscription, and maintenance on easy comparisons with the exception of professional services, which rebounded sharply in the third…

Read More